PCOS Patients' Immune Alterations

Launched by SHANGHAI 10TH PEOPLE'S HOSPITAL · Mar 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how the immune system functions in women with Polycystic Ovary Syndrome (PCOS). Researchers want to understand the unique characteristics of the immune system in these patients compared to healthy women. To do this, they will collect blood samples from participants and analyze them using a special technique called flow cytometry. This study aims to help create a method for evaluating immune function in women with PCOS, which could lead to better understanding and treatment options.

Women between the ages of 18 and 45 who have been diagnosed with PCOS may be eligible to join the study. To qualify, they must meet specific criteria related to their menstrual cycles and hormone levels. Participants will be asked to voluntarily join the study and sign an informed consent form. If you decide to participate, you can expect to provide a blood sample for testing and contribute to important research that could help improve care for women with PCOS in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female subjects aged 18-45 years;
• • Voluntarily participate in the experiment, willing to sign the informed consent.
• • According to the Rotterdam consensus, polycystic ovarian syndrome (PCOS) needs to meet the presence of two of three of the following criteria: oligo-anovulation, hyperandrogenism, and polycystic ovaries (≥ 12 follicles measuring 2-9 mm in diameter and/or an ovarian volume \> 10 mL in at least one ovary).
• Exclusion Criteria:
• • Female patients younger than 18 years old or older than 45 years old;
• • Ovulation disorders caused by premature ovarian failure, pituitary amenorrhea, hypothalamic amenorrhea, and thyroid dysfunction (hyperthyroidism, hypothyroidism);
• • Congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, adrenal tumors, and other diseases causing hyperandrogenemia;
• • Severe liver and kidney dysfunction (more than 3 times the normal value)
• • Type 1 diabetes, monogenic mutation diabetes, diabetes due to pancreatic injury or other secondary diabetes;
• • History of malignant tumor;
• • Severe infection, severe anemia, neutropenia, and other chronic diseases of the system;
• • Patients undergoing total hysterectomy or ovarian adnexectomy;
• • Mental illness, dementia, or other cognitive behavioral problems;
• • Hypoglycemic drugs that may affect insulin resistance and androgen levels, including thiazolidinedione, metformin, SGLT-2i, acarbose, and glucagon-like peptide-1 receptor agonist (GLP-1RA), have been used in the past 3 months;
• • Take letrozole, clomiphene, oral contraceptives, glucocorticoids, gonadotropins, gonadotropin-releasing hormone agonists, antiandrogens (spironolactone, cyproterone acetate, flutamide, etc.), and other medications for PCOS treatment within the last 3 months.
• • Pregnant or lactating patients;
• • Female patients with a BMI less than 20kg/m2.